Intra-Cellular Therapies Inc. (NASDAQ:ITCI)‘s stock had its “outperform” rating restated by equities research analysts at Cowen and Company in a research report issued on Friday, The Fly reports. They presently have a $27.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $20.00. Cowen and Company’s target price suggests a potential upside of 26.23% from the stock’s current price.

ITCI has been the topic of a number of other reports. ValuEngine lowered shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $14.00 price target on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a research report on Thursday, August 24th. Leerink Swann raised shares of Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 23rd. Finally, Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, May 16th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $25.11.

Intra-Cellular Therapies (NASDAQ ITCI) traded down 3.21% on Friday, hitting $21.39. 828,691 shares of the stock traded hands. The stock has a 50 day moving average of $13.42 and a 200 day moving average of $12.73. Intra-Cellular Therapies has a 52 week low of $7.85 and a 52 week high of $45.20. The firm’s market capitalization is $928.84 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.33. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.03 million. During the same period last year, the firm earned ($0.71) earnings per share. The firm’s revenue was down 52.2% on a year-over-year basis. Equities research analysts anticipate that Intra-Cellular Therapies will post ($2.36) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Receives Outperform Rating from Cowen and Company” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/08/intra-cellular-therapies-inc-itci-receives-outperform-rating-from-cowen-and-company.html.

A number of hedge funds have recently made changes to their positions in the business. Wasatch Advisors Inc. increased its stake in shares of Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after purchasing an additional 654,400 shares in the last quarter. Clough Capital Partners L P increased its stake in shares of Intra-Cellular Therapies by 157.0% in the first quarter. Clough Capital Partners L P now owns 898,750 shares of the biopharmaceutical company’s stock worth $14,605,000 after purchasing an additional 549,100 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Intra-Cellular Therapies by 419.3% in the second quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after purchasing an additional 522,565 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Intra-Cellular Therapies by 336.1% in the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after purchasing an additional 447,586 shares in the last quarter. Finally, BB Biotech AG increased its stake in shares of Intra-Cellular Therapies by 22.2% in the first quarter. BB Biotech AG now owns 1,925,000 shares of the biopharmaceutical company’s stock worth $31,281,000 after purchasing an additional 350,000 shares in the last quarter. 71.79% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

The Fly

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.